Only one study to date has identified a predictive value for this marker in a retrospective cohort of patients with ovarian cancer, which was incorporated into a nomogram designed to predict VTE, along with hormone receptor status (i.e., PR and ER), and age [50]. This evidence concerns the gene ESR1 and ovarian cancer.